NNC0109-0012 + placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Rheumatoid Arthritis
Trial Timeline
Aug 1, 2012 → Nov 1, 2014
NCT ID
NCT01636817About NNC0109-0012 + placebo
NNC0109-0012 + placebo is a phase 2 stage product being developed by Novo Nordisk for Inflammation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01636817. Target conditions include Inflammation, Rheumatoid Arthritis.
What happened to similar drugs?
2 of 15 similar drugs in Inflammation were approved
Approved (2) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01636843 | Phase 2 | Terminated |
| NCT01636817 | Phase 2 | Terminated |
Competing Products
20 competing products in Inflammation